Transcription of Revisiting JPN
{{id}} {{{paragraph}}}
Example: bankruptcy
Revisiting JPN
13 . Revisiting JPN - . 3.. TKI . - - , 1) 2). 3), 4). 1) , 2) . 3) , 4) .. 06/16/12. P-I/II of IFN- and low dose IL-2 for mRCC. - Overall responses - Response n CR PR MR NC PD rate (%) 95CI . P-I 9 - 4 1 4 - P-II 37 - 8 2 14 13 IL-2 : x 106 Japan reference unit (JRU)/person for 5 days a week (Akaza H. Int. J. Clin. Oncol. 11 434, 2006). IFN 2b and Thalidomide in the treatment of mRCC. Overall survival Time to treatment failure Mos (Hernberg M et al. J Clin Oncol 21:3770,2003). Sorafenib Study 100391 Trial Schema 25% Shrinkage Continue Sorafenib Open Label Sorafenib 12 Week >-25% to <25% Tumor Induction Randomized Assessment 25% Growth Placebo*. Off study Base line 12 wks 24wks * May cross over to Sorafenib (Ratin MJ et al. ASCO, 2004 ). RCC in Hamamatsu Univ. Sch. of Med. Cases M0 M1. 90. 80. (n=1059, ). 70. 60. 50. 40. 30. 20. 10. 0. 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006.
IFN α2b and Thalidomide in the treatment of mRCC (Hernberg M et al. J Clin Oncol 21:3770,2003) Mos Overall survival Time to treatment failure
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: